Journal profile · Neurosciences
CNS Neuroscience & Therapeutics
ISSN 1755-5930 · eISSN 1755-5949 · Wiley-Blackwell Publishing Ltd · ENGLAND · Quarterly · Founded 2008
CNS Neuroscience & Therapeutics: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.49; fully open access; APC about USD 4,550; median 155 days to acceptance (145 articles, last 24 months); community-reported acceptance: about 75%; 560 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
CNS Neuroscience & Therapeutics is published by Wiley-Blackwell Publishing Ltd and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Neuroinflammation and Neurodegeneration Mechanisms, Functional Brain Connectivity Studies and Neuroscience and Neuropharmacology Research, together about 22.7% of its articles. Its main subfields are Neurology. (generated from OpenAlex topic counts and CAS ranking data)
CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, and drug abuse.
From the journal's Aims & Scope
Research area (LetPub): Neurosciences
Editor-in-chief Tian-Ming GaoPublisher website
Editorial board by country: 37 in mainland China (about 41%); most named Mainland China 37, United States 29, France 7, United Kingdom 3, India 3 (91 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience10.9%
- Functional Brain Connectivity StudiesNeuroscience5.9%
- Neuroscience and Neuropharmacology ResearchNeuroscience5.9%
- Alzheimer's disease research and treatmentsMedicine5.7%
- Parkinson's Disease Mechanisms and TreatmentsMedicine5.6%
- Neurological disorders and treatmentsMedicine5.2%
- Neurogenesis and neuroplasticity mechanismsNeuroscience4.8%
- Neurological Disease Mechanisms and TreatmentsNeuroscience4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
| Minor | Neurosciences | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Neurosciences | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Neurosciences | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.49LetPub ·
- CiteScore 2026-06
- 8.5LetPub ·
- SJR 2026-06
- 1.74LetPub ·
- SNIP 2026-06
- 1.29LetPub ·
- h-index
- 59LetPub ·
- h-index
- 121OpenAlex ·
- i10-index
- 2,148OpenAlex ·
- 2-year mean citedness
- 6.11OpenAlex ·
- Self-citation rate
- 3%LetPub ·
- Share of gold OA articles
- 99.93%LetPub ·
Volume
- Articles per year
- 493LetPub ·
Articles by year OpenAlex count · 4,288 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 459 | 459 | 216 |
| 2025 | 560 | 560 | 2,686 |
| 2024 | 557 | 557 | 6,735 |
| 2023 | 503 | 503 | 9,203 |
| 2022 | 296 | 296 | 6,375 |
| 2021 | 203 | 203 | 5,117 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
155 daysMedian, submission to acceptance · P25–P75 107 days – 214 days
- Acceptance to online
- median 16 days (145 articles)
- Submission to online
- median 177 days
- Sample
- 145 articles with submission and acceptance dates (1,103 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 75%LetPub ·
- Submission to publication (journal-reported)
- about 14 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,550 / GBP 3,140 / EUR 3,900 | Yes | CC BY | |
| OpenAlex | USD 4,140 / EUR 3,550 / GBP 3,140 | — | — | |
| LetPub | USD 3,410 / GBP 2,590 / EUR 2,920 | Yes | — | |
| Publisher website | No APC | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Reference style
- Numbered, in order of citation
- First submission
- Free format: the journal's layout is not required
- Graphical abstract
- Required
Article types accepted7, with length limits
- editorialce or tone of a letter or response. (5) Editorials Word Limit: 1500 words maximum. Abstract: not required. References: 5 maximum. Desmain text ≤ 1,500 words
- letterStudies in Epidemiology) checklist. (9) Letter to the Journal Word limit: 1000 words maximum. Abstract: not required. References: 10 maximum. Fimain text ≤ 1,000 words
- letters to the editorll be influenced by the guidelines. (4) Letters to the Editor Word limit: 1000 words maximum. Abstract: not required. References: 10 maximum. Fimain text ≤ 1,000 words
- meta-analysised paper for initial consideration. (8) Meta-Analyses Word limit: 4000 words maximum including abstract but excluding references, tablesmain text ≤ 4,000 words
- original article(1) Original Articles Word limit: 4000 words maximum including abstract but excluding references, tables and figures. Abstract: 200 words maximum, with sub-head…main text ≤ 4,000 words
- original articles(1) Original Articles Word limit: 4000 words maximum including abstract but excluding references, tables and figures. Abstract: 200 words maximum, with sub-head…Length not stated
- reviewn either basic or clinical science. (2) Reviews Word limit: 4000 words maximum including abstract but excluding references, tablesmain text ≤ 4,000 words
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Plagiarism
- AI use
From 1st January 2025, all submissions and reviews must adhere to artificial intelligence (AI) guidelines. Note: CNS Neuroscience & Therapeutics adopts Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics – Artificial Intelligence. Model summary
From 1st January 2025, all submissions and reviews must adhere to artificial intelligence (AI) guidelines. Note: CNS Neuroscience & Therapeutics adopts Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics – Artificial Intelligence.
Source ↗Publisher website ·- Authorship Authorship and Acknowledgements
The journal adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship be based on the following 4 criteria: i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; ii) Drafting the work or revising it critically for importa…
Source ↗Publisher website ·- Conflicts of interest Disclosure
All manuscripts must include a disclosure statement in the body of the manuscript. The statement must declare any financial support or relationships that may pose conflict of interest. This includes any financial arrangements authors have with a company whose product figures prominently in the submitted manuscript or with a company making a competing product. The absence of any interest to disclos…
Source ↗Publisher website ·- Data availability Data Availability Statement
A statement to confirm the presence or absence of shared data. If authors have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data. Authors will be required to confirm adherence to the policy. Sample statements are available here. If published, al…
Source ↗Publisher website ·- Publication ethics Committee on Publication Ethics
The journal is a member of, and subscribes to the principles of the Committee on Publication Ethics (COPE). Model summary
The journal is a member of, and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·- License & copyright Reproduction of Copyright Material
If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is the author’s responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Copyright Terms & Conditions FAQ at http://exchanges.wiley.com/authors/faqs---copyright-terms--conditions_301.html
Source ↗Publisher website ·- Open access Relevant Open Access Health Sciences journals
Animal Models and Experimental Medicine (2018-Present)Brain Pathology (1990-Present)Ibrain (2020-Present)Neuroprotection (2022-Present)Brain-X (2023-Present)
Source ↗Publisher website ·- Peer review 2. EDITORIAL AND PEER REVIEW CONSIDERATIONS
CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and ps…
Source ↗Publisher website ·- Plagiarism Plagiarism Detection
The journal employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell Publishing Ltd
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Quarterly
- Founded
- 2008
- ISSN
- 1755-5930
- Electronic ISSN
- 1755-5949
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about CNS Neuroscience & Therapeutics
What CAS zone is CNS Neuroscience & Therapeutics in?
In the 2025 upgraded edition of the CAS Journal Ranking, CNS Neuroscience & Therapeutics is in Zone 2 of Medicine, and in Zone 2 of the minor category Pharmacology & Pharmacy / Neurosciences. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of CNS Neuroscience & Therapeutics?
The latest impact factor listed by LetPub is 6.49; CiteScore 8.5, h-index 121.
How long does peer review take at CNS Neuroscience & Therapeutics?
Based on the dates recorded on 145 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 155 days (interquartile range 107–214 days); authors report an average review time of about 2 months; the community-reported acceptance is “about 75%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of CNS Neuroscience & Therapeutics?
According to the journal's author guidelines: Reference style: Numbered, in order of citation; First submission: Free format: the journal's layout is not required; Graphical abstract: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of CNS Neuroscience & Therapeutics based?
Of the 91 board members whose country the journal's board page names, 37 (about 41%) are in mainland China; the countries named most often are Mainland China (37), United States (29) and France (7). Counted from the institutions listed on the board page; for reference only.
Which databases index CNS Neuroscience & Therapeutics?
According to LetPub and DOAJ records, CNS Neuroscience & Therapeutics is indexed in SCIE, Scopus and DOAJ.
Is CNS Neuroscience & Therapeutics open access, and what is the APC?
CNS Neuroscience & Therapeutics is a fully open-access journal. APC about USD 4,550.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .